Table 1. Reported results of single agent checkpoint inhibitors trials in recurrent glioblastoma.

Registration number	Treatment	Overall response rate* (%), (N)	Comments
NCT02017717	Nivolumab	8% (n=153) [8]	Longer duration of response (11.1 mo compared to 5.3 mo for bevacizumab). Median PFS 1.5 months. 12-month OS 42%.
NCT02054806	Pembrolizumab	4% (n=26) [53]	Median OS 14.4 months. Median PFS 2.8 months.
NCT02336165	Durvalumab	13.3% (n=31) [9]	12-month OS 44.4% 6-month OS 59.0% 6-month PFS 20.0%

^* Overall response rate according to RANO criteria.

PFS- progression-free survival.

OS- overall survival.